Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

April 8, 2016

Primary Completion Date

August 15, 2018

Study Completion Date

November 29, 2023

Conditions
Breast Cancer
Interventions
DRUG

Palbociclib 100mg

100mg PO daily

DRUG

Palbociclib 125mg

125mg PO daily 3 weeks out of 4

DRUG

Fulvestrant or Tamoxifen or Aromatase Inhibitor

given at the standard doses/schedules

Trial Locations (22)

T6G 1Z2

Cross Cancer Institute, Edmonton

V2S 0C2

BCCA - Abbotsford Centre, Abbotsford

V3V 1Z2

BCCA - Fraser Valley Cancer Centre, Surrey

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

E1C 6Z8

The Moncton Hospital, Moncton

A1B 3V6

Dr. H. Bliss Murphy Cancer Centre, St. John's

B3H 1V7

QEII Health Sciences Centre, Halifax

L4M 6M2

Royal Victoria Regional Health Centre, Barrie

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K7L 5P9

Cancer Centre of Southeastern Ontario at Kingston, Kingston

L3Y 2P9

Stronach Regional Health Centre at Southlake, Newmarket

L1G 2B9

Lakeridge Health Oshawa, Oshawa

K1H 8L6

Ottawa Hospital Research Institute, Ottawa

L2S 0A9

Niagara Health System, St. Catharines

M5G 2M9

University Health Network, Toronto

N8W 2X3

Windsor Regional Cancer Centre, Windsor

H2L 4M1

CHUM - Hopital Notre-Dame, Montreal

H3T 1E2

The Jewish General Hospital, Montreal

H4J 1C5

Hopital du Sacre-Coeur de Montreal, Montreal

G1S 4L8

CHA-Hopital Du St-Sacrement, Québec

J1H 5N4

Centre hospitalier universitaire de Sherbrooke, Sherbrooke

S4T 7T1

Allan Blair Cancer Centre, Regina

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Canadian Cancer Trials Group

NETWORK